Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:36:13 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:TGTX from 2023-04-20 to 2024-04-19 - 34 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-18 07:30U:TGTXNews ReleaseTG Therapeutics Announces Additional Data Presentations for BRIUMVI(TM) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-04-18 07:00U:TGTXNews ReleaseTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
2024-04-15 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-08 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-01 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-02-28 07:00U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
2024-02-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Issuance of Additional Patents for BRIUMVI(TM) (ublituximab-xiiy)
2024-02-26 07:00U:TGTXNews ReleaseTG Therapeutics Announces European Launch of BRIUMVI(TM) (ublituximab-xiiy)
2024-02-23 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
2024-02-20 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI ‚ ® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-01-10 07:00U:TGTXNews ReleaseTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
2024-01-09 07:00U:TGTXNews ReleaseTG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision ¢ € ™s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
2024-01-05 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-27 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-03 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
2023-11-01 07:30U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-10-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
2023-10-12 11:00U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-11 10:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-02 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-09-22 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
2023-09-07 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-01 07:15U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-08-01 07:00U:TGTXNews ReleaseTG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI ‚ ® (ublituximab-xiiy)
2023-07-31 08:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
2023-06-05 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-06-02 09:15U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI ‚ ® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
2023-06-01 09:15U:TGTXNews ReleaseTG Therapeutics Announces European Commission Approval for BRIUMVI ‚ ® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
2023-05-31 07:30U:TGTXNews ReleaseTG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI ‚ ® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
2023-05-04 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
2023-05-01 07:30U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
2023-04-28 16:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
2023-04-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI ‚ ® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
2023-04-25 08:00U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI ‚ ® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting